BIRMINGHAM, Ala., May 2, 2023 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the BofA Securities 2023 Healthcare Conference being held in Las Vegas May 9-11, 2023.
Encompass Health's Executive Vice President and Chief Financial Officer Doug Coltharp will present during a fireside chat on Tuesday, May 9, 2023, at 8 a.m. PT.
The presentation will be webcast live and available at http://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 157 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's 100 Best Companies to Work For and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media Contact
Casey Winger | 205 970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact
Mark Miller | 205 970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$100.23 |
| Daily Change: | -1.11 -1.10 |
| Daily Volume: | 776,330 |
| Market Cap: | US$10.090B |
November 04, 2024 October 28, 2024 August 05, 2024 July 30, 2024 July 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
